Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Recruiting now Phase 3 NCT06846281
Run by Novartis Pharmaceuticals · for 40 to 70 · All sexes
What this study is about
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Who can join (things the study team will check)
✅ You may be able to join if…
- Male or female aged 40 to 70 years (inclusive)
- Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
- Treated with ocrelizumab according to routine clinical practice and at standard dose
- Neurologically stable within 30 days
- Suitable to be switched to remibrutinib based on physician judgement or patient preference
🚫 You may not be able to join if…
- Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria
- History of clinically significant Central Nervous System disease or neurological disorders
- History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent
- Active clinically significant systemic bacterial, viral, parasitic or fungal infections
- Active, chronic disease of the immune system other than MS
- Severe cardiac disease or significant findings on the ECG
- Participant who is unable to undergo MRI scans
- History of life-threatening infusion or injection reaction related to ocrelizumab Other inclusion and exclusion criteria may apply
Where this trial is running
- Perseverance Research Center, Scottsdale, Arizona, United States
- University of California Irvine, Irvine, California, United States
- Medstar Washington Hospital Center, Washington D.C., District of Columbia, United States
- Neurology of Central FL Res Ctr, Altamonte Springs, Florida, United States
- University of Florida, Gainesville, Florida, United States
- Neurology Associates PA, Maitland, Florida, United States
- Aqualane Clinical Research, Naples, Florida, United States
- Advent Health Orlando, Orlando, Florida, United States
- Orlando Health Clinical Trials, Orlando, Florida, United States
- Tallahassee Neurological Clinic, Tallahassee, Florida, United States
- University Of South Florida, Tampa, Florida, United States
- Vero Beach Neurology, Vero Beach, Florida, United States
+ 108 more sites.
Who to contact
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06846281.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.